South Korean Biotech Sector Surges on Global Pharma Partnerships[K-bio Pulse]

작성일 08-19

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
         <section dmcf-sid="BFq9eZrRs3">
          <div contents-hash="e08172032f49daf28e49a8625cdbdd8b7270a571614a611474d2b0c5822d07d8" dmcf-pid="b3B2d5merF" dmcf-ptype="general">
           <div>
            이 기사는 2025년08월18일 10시00분에 <strong>팜이데일리 프리미엄 콘텐츠</strong>로 선공개 되었습니다.
           </div>
          </div>
          <p contents-hash="0a3d4dcaf05a45395e91507c6373659b3b19fda1cb55bc6398b80249915114f4" dmcf-pid="K0bVJ1sdOt" dmcf-ptype="general">[Seungkwon Kim, Edaily Reporter] South Korean biotechnology stocks surged Thursday as G2GBIO made a spectacular trading debut and established pharmaceutical companies posted strong earnings, driven by expectations for global partnerships and breakthrough obesity treatments.</p>
          <p contents-hash="f44597b46c766b097c9a6c9fecf8499107a6d413e0c31f6bcffb472b8ebba1c8" dmcf-pid="9pKfitOJI1" dmcf-ptype="general"><strong> G2GBIO‘s Remarkable Market Entry</strong></p>
          <p contents-hash="692fce73c32f17e5fe7ffb84f8ad509f1802dc4943a59a57de501a37c9fbbf53" dmcf-pid="2U94nFIim5" dmcf-ptype="general">G2GBIO, a pharmaceutical development company specializing in long-acting injectable drug delivery systems, closed its first trading day at 93,800 won ($70.21), up 61.72% from its initial public offering price of 58,000 won. The strong debut came despite earlier concerns about the company’s financial losses and competitive subscription rates.</p>
          <p contents-hash="d3eaf6a609e22eae5faf470c4a0221c4ee1436b9b5d4226fafc21f160d73d084" dmcf-pid="Vu28L3CnEZ" dmcf-ptype="general">The company‘s IPO attracted 470.1-to-1 competition ratio for retail investors, significantly lower than recent biotech listings but reflecting cautious sentiment toward loss-making biotechs. G2GBIO has reported losses exceeding 10 billion won annually for the past three years, with deficits expected to continue into next year.</p>
          <figure class="figure_frm origin_fig" contents-hash="ee8116a4ef6a56c7a2bbe01afccb6815eddf1918819c4b0ff4124996d43191e5" dmcf-pid="fH076yA8rX" dmcf-ptype="figure">
           <p class="link_figure"><img alt="A general view of G2GBIO headquarters (Photo courtesy of G2GBIO)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202508/19/Edaily/20250819120142278szxe.jpg" data-org-width="490" dmcf-mid="zoYZqmdzOp" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202508/19/Edaily/20250819120142278szxe.jpg" width="658"></p>
           <figcaption class="txt_caption default_figure">
            A general view of G2GBIO headquarters (Photo courtesy of G2GBIO)
           </figcaption>
          </figure>
          <div contents-hash="43eaf9624ccf2ff99a63af053086b2b3be4baacb2cca150bbfc064a1df9ca3d0" dmcf-pid="4XpzPWc6IH" dmcf-ptype="general">
           The rally was fueled by investor optimism over G2GBIO’s proprietary InnoLAMP platform technology, which extends drug efficacy duration in the body for several months. The company has signed development contracts with German pharmaceutical giant Boehringer Ingelheim and secured partnerships with two additional global pharmaceutical companies.
          </div>
          <p contents-hash="676d054c0e35dc77c4be1d0b73a96775f4eca7071453344613bd2f2ccc918704" dmcf-pid="8ZUqQYkPEG" dmcf-ptype="general"><strong> GLP-1 Market Driving Growth Expectations</strong></p>
          <p contents-hash="2d21260c69d0d6d2ef5e94490573a83a5818c4895f01f290b9b857ee263742b2" dmcf-pid="65uBxGEQDY" dmcf-ptype="general">Market analysts attributed G2GBIO‘s strong performance to rising expectations for its GLP-1 obesity treatment pipeline. The global GLP-1 agonist market, valued at $47.74 billion in 2024, is projected to grow at 10.9% annually through 2034. GLP-1 drugs like semaglutide have shown remarkable success in weight management, creating significant opportunities for companies with extended-release formulations.</p>
          <p contents-hash="5806b3f3b7669f849d0a1c94d62e419e1407cca5ed132e678d62a58fa4eaec31" dmcf-pid="P17bMHDxOW" dmcf-ptype="general">G2GBIO’s technology platform could potentially develop once-monthly alternatives to current weekly GLP-1 injections, addressing a major market need for improved patient compliance and convenience.</p>
          <p contents-hash="ab0785695c90477578e840bb48843acdc5d54194e0cb30c365520dcab08c52a0" dmcf-pid="QtzKRXwMsy" dmcf-ptype="general"><strong> Established Players Post Strong Results</strong></p>
          <p contents-hash="4b46351787bcdcd9949bc58e2baf3f929a5de8d5910edc7dc4e7c2c051f7af2d" dmcf-pid="xFq9eZrRIT" dmcf-ptype="general">Kangstem Biotech surged 14.4% to close at 1,340 won, driven by anticipated partnerships with global pharmaceutical giants, including a major U.S. healthcare company known as “J&amp;J”. The stem cell therapy developer is reportedly in final approval stages for organoid business collaboration with Johnson &amp; Johnson, focusing on skin disease model evaluation.</p>
          <figure class="figure_frm origin_fig" contents-hash="bd6112b193d09e3847c1e323c250e280d554f59626ea99c6447a1594a6bdc1a6" dmcf-pid="ygDsGibYEv" dmcf-ptype="figure">
           <p class="link_figure"><img alt="Kangstem Biotech stock price trend (Data: KG Zeroin)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202508/19/Edaily/20250819120144474qtoj.jpg" data-org-width="490" dmcf-mid="q4mCZo2Xw0" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202508/19/Edaily/20250819120144474qtoj.jpg" width="658"></p>
           <figcaption class="txt_caption default_figure">
            Kangstem Biotech stock price trend (Data: KG Zeroin)
           </figcaption>
          </figure>
          <div contents-hash="42e01d51065dfaa8be8ce0a4937645700017fdd4db44ca4eb9e02f37d6438415" dmcf-pid="WhG5BsJqsS" dmcf-ptype="general">
           Kangstem‘s organoid technology has attracted interest from multiple global pharmaceutical companies seeking alternatives to animal testing for drug development. The company’s three-dimensional cell culture technology can replicate actual skin structure, including hair follicles, sebaceous glands and melanin cells.
          </div>
          <p contents-hash="d4b62367a73447bb067cc320bd40e7f8f6e3f8fb3bcd6b03a3dea79d09059018" dmcf-pid="YlH1bOiBIl" dmcf-ptype="general">Prestige BioPharma Group climbed approximately 10% to 15,720 won after reporting record-breaking revenue performance. The biosimilar developer achieved consolidated revenue of 14.3 billion won for the fiscal year ending June 2025, representing significant year-over-year growth.</p>
          <p contents-hash="2d41ee806e01936ecb972dc3ee5d3ed23bd3d6c0c95a9b450d8a9c9f3238d582" dmcf-pid="GSXtKInbOh" dmcf-ptype="general">The company‘s Herceptin biosimilar “Tuzneu” received European market authorization in September 2024, leading to expanded milestone revenue recognition. Prestige BioPharma secured licensing and supply agreements with Teva Pharmaceuticals for 31 European countries in May 2025.</p>
          <p contents-hash="14eda74ac461ce1f17711f0d56405375794ab485121ac6bc04d538ad7826669e" dmcf-pid="HvZF9CLKEC" dmcf-ptype="general"><strong> Market Context and Outlook</strong></p>
          <p contents-hash="9c8e4346bbcb07aed054d0926fbe2d513a3b174188cd83efc8cb6eb0d70e0b40" dmcf-pid="XT532ho9rI" dmcf-ptype="general">The biotechnology rally reflects broader trends in South Korea’s healthcare sector, which has outperformed traditional technology stocks in recent months. The KRX Healthcare Index rose 22.7% in the second half of 2024, while semiconductor stocks declined 22.1%.</p>
          <p contents-hash="952ef6aeffed5b4cb55184f10faac299be89b516eff228c905fe407fe3a7a76f" dmcf-pid="Zy10Vlg2DO" dmcf-ptype="general">Industry analysts cite several factors supporting continued biotech momentum, including U.S. interest rate cuts creating favorable funding conditions, potential benefits from U.S. legislation targeting Chinese contract manufacturers, and increasing success rates for Korean companies in global partnerships.</p>
          <p contents-hash="9a14036a979c2bd0ede3631dff12bcf42ef77343e90dbcf0bd3edc9c41708396" dmcf-pid="5WtpfSaVrs" dmcf-ptype="general">The sector‘s performance has been bolstered by successful technology transfers and collaborations with major international pharmaceutical companies, validating South Korean biotech capabilities and market potential.</p>
          <p contents-hash="916a2ccfa28f4d2f79cadb37a02dae2e4b1207c385a74d62cc8caf2459a9fbaa" dmcf-pid="1YFU4vNfsm" dmcf-ptype="general">G2GBIO plans to use IPO proceeds for expanding manufacturing capacity through first factory expansion and second factory construction, positioning for increased production scale as pipeline development progresses.</p>
          <p contents-hash="6b87162050bec0a6ae4042f03c579c1a1595235d7046edaf9800060064db0657" dmcf-pid="tG3u8Tj4sr" dmcf-ptype="general">김승권 (peace@edaily.co.kr) </p>
         </section> 
        </div> 
        <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>

이전

조현영 "공개연애 NO" 외치더니…배정남과 묘한 기류 ('돌싱포맨')

08-19
다음

‘쪽쪽이’ 세레모니 헤이스…“더 높은 곳 약속”

08-19

등록된 댓글이 없습니다.

로그인한 회원만 댓글 등록이 가능합니다.

먹튀폴리스

South Korean Biotech Sector Surges on Global Pharma Partnerships[K-bio Pulse]

멤버랭킹

관련자료

멤버랭킹